RxDoctor Payments DataLook up a doctor →

Sunil Gupta, MD

Retina Specialist · Pensacola, FLNPI 1063489383

Payments from drug & device makers

$8,127,870in general payments, 2019–2025

Across 1,049 payments — averaging $7748.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$4.1M
  • US Retina LLC$1.8M
  • Novartis$609K
  • Ocular Therapeutix, Inc.$436K
  • Apellis Pharmaceuticals, Inc.$358K
  • Bayer$317K
  • plus $546K from 29 others
$55,165in research payments, 2019–2025

Across 7 payments — averaging $7880.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$54K
  • F. Hoffmann-la Roche AG$1K

What the payments were for

  • Consulting fees$13,1011%
  • Travel & lodging$4,3600%
  • Food & beverage$7,7740%
  • Entertainment$180%
  • Ownership interest$1,216,82967%
  • Other$574,32032%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,127,870 in reported general payments places this provider in the 95th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$16,797,721
Medicare patients
2,020
Services billed
162,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac41$21,186
Prednisolone Acetate246$12,523
Bromfenac Sodium51$12,039
CombiganBrimonidine Tartrate/Timolol25$6,693
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$5,977
ProlensaBromfenac Sodium12$4,555
Difluprednate30$3,462
Cyclosporine14$2,974
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat155$2,880
Acetazolamide55$1,919
Brimonidine Tartrate73$1,890
Timolol Maleate118$1,880
Latanoprost113$1,635
MoxifloxacinMoxifloxacin Hcl77$1,628
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha125$1,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$609,396$21,18641 claims
AbbVieCombigan$24,192$6,69325 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$19$4,55512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →